Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) Compared to Fluzone® Quadrivalent in Children 6 to 35 Months of Age

NCT02242643 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

2432

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza

Interventions

BIOLOGICAL: FluLaval™ Quadrivalent
BIOLOGICAL: Fluzone® Quadrivalent

Sponsor

GlaxoSmithKline